The Health Sciences Authority (HSA) has approved Sanofi and AstraZeneca's BEYFORTUS (nirsevimab) for the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease in newborns and ...

With the approach of fall likely bringing the usual uptick in respiratory illness, the provincial government is boosting its ...

Sanofi’s shift to immunology, AI-driven R&D, and strong pipeline offset risks from patent cliffs and legal issues. See why SNY stock is a strong buy.

RSV is the leading cause of hospitalization in US infants, and in August 2023, the CDC’s vaccine advisory group recommended ...

Palivizumab injection (Synagis), an RSV prevention therapy for children, is being discontinued and will no longer be available as of December 31, 2025.

The company also records Beyfortus product sales from products supplied to partner Sanofi under the V&I Therapies segment. AstraZeneca’s Key Oncology Drugs Beat Estimates ...

Moderna, Inc.'s Q2 2025 earnings highlight a steep revenue decline post-pandemic, with just $0.1bn in revenue and a $(0.8bn) net loss. Learn more on MRNA stock here.

For infants born from October to February, maternal vaccination was cost-effective, but compared with vaccination, nirsevimab was cost-effective only in those born in October and November.

HHS Secretary Robert F. Kennedy Jr. last month quietly endorsed recommendations from his handpicked vaccine advisors that everyone in the U.S. ages 6 months and older receive a flu shot for the ...

If approved, Beyfortus would become the first and only single-dose, passive immunisation for a broad infant population, including those born healthy, at term or preterm, or with specific health ...